| Prev Close | 0.71 |
| Open | 0.70 |
| Day Low/High | 0.67 / 0.76 |
| 52 Wk Low/High | 0.65 / 3.42 |
| Volume | 5.80M |
| Avg Volume | 2.32M |
| Exchange | NASDAQ |
| Shares Outstanding | 141.07M |
| Market Cap | 98.54M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the August 2018 expiration.
The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the December 15th expiration.
The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,261,068 share decrease in total short interest for Celldex Therapeutics, Inc. , to 7,177,400, a decrease of 42.30% since 09/15/2017.
Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the May 2018 expiration.
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the October 20th expiration.
Conference Call Scheduled for Tuesday, August 8 at 4:30 p.m. Eastern Time
Conference Call Scheduled for Tuesday, August 8 at 4:30 p.m. Eastern Time
Investors in Celldex Therapeutics, Inc. saw new options become available today, for the September 15th expiration.
Early signs of clinical activity without increased toxicity observed
Combination study with checkpoint inhibitor currently enrolling; data from combination arm with varlilumab anticipated in fall of 2017
Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.
Conference Call Scheduled for 4:30 p.m. ET Today
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.
